FDA Announces Pulmonary-Allergy Drugs Advisory Committee Meeting to Discuss New Treatments for Respiratory Conditions

Summary

The US Food and Drug Administration (FDA) has scheduled a meeting of the Pulmonary-Allergy Drugs Advisory Committee to discuss new treatments for respiratory conditions, including asthma and chronic obstructive pulmonary disease (COPD)